Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 891 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cytarabine Clear all
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01249430
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Cytarabine, Etoposide Phosphate, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Jul 23, 2026, 3:33 PM EDT
Not listed Phase 2 Interventional

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

NCT03736616
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Carboplatin, Ifosfamide, Etoposide, Rituximab, Carmustine, Cytarabine, Melphalan, Autologous HSCT, Acalabrutinib
Drug · Biological · Other
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 2 Interventional

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00007852
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01130506
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

NCT00521014
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, sargramostim, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

NCT02577406
View directory record Official record
Conditions
Leukemia, Myeloid, Isocitrate Dehydrogenase
Interventions
AG-221, BSC, Azacitidine, Low-dose cytarabine (LDAC), Intermediate-dose cytarabine (IDAC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
60 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 23, 2026, 3:33 PM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

NCT00594555
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia
Interventions
Imatinib Mesylate, CLAG
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2008 · Synced Jul 23, 2026, 3:33 PM EDT
Terminated Phase 2 Interventional Results available

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

NCT00939653
View directory record Official record
Conditions
Relapsed Acute Myelogenous Leukemia
Interventions
Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00002945
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Jul 23, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

NCT03926624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

NCT02582359
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
MLN9708, Cytarabine, Daunorubicin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

NCT00064090
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytarabine, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT00940524
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jul 23, 2026, 3:33 PM EDT
Withdrawn Phase 1 Interventional

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

NCT00957320
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Sirolimus, PEG-asparaginase
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

NCT02323607
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Pacritinib, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Bhavana Bhatnagar
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 3:33 PM EDT
Recruiting Phase 2 Interventional

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT06918431
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 54 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

NCT02768792
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse
Interventions
pembrolizumab,
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 23, 2026, 3:33 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

NCT02351037
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Ibrutinib, Ibrutinib + LD-AraC, Ibrutinib+Azacitidine
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

NCT01147939
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Elacytarabine, Investigator's Choice
Drug
Lead sponsor
Clavis Pharma
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Jul 23, 2026, 3:33 PM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

NCT03488225
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jul 23, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Results available

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02971397
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis
Procedure · Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 23, 2026, 3:33 PM EDT